文献速递心力衰竭与心肌病

终末期心衰患者心肌成纤维细胞表型与纤维化可逆性

Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2019-01-01

研究从缺血性与扩张型心肌病心脏移植受者及未使用供体心脏分离左室成纤维细胞,培养4或8天并行功能、免疫染色及表达研究,辅以组织免疫组化。结果显示心衰心脏间质纤维化伴交联胶原沉积、活化肌成纤维细胞存在,TGF-β1等升高;抑制TGF-β1受体激酶可促去分化并降低促纤维化基因与细胞因子至非心衰水平。

要点

  • 终末期心衰心脏以间质纤维化伴交联胶原及活化肌成纤维细胞为特征
  • 心衰来源成纤维细胞主要为肌成纤维细胞,TGF-β1通路激活
  • 抑制TGF-β1受体激酶可促肌成纤维细胞去分化并降低促纤维化表达

核心结论

  • 终末期心衰的肌成纤维细胞具有不同程度分化且保留向低活化状态逆转的能力,提示靶向肌成纤维细胞抗纤维化治疗具潜力。

研究设计与样本

  • 从心脏移植受者(缺血性与扩张型心肌病)摘除左室及未使用供体心脏分离成纤维细胞,不传代培养4或8天行处理研究。
  • 表型分析包括功能测试、免疫染色及分化标志物表达研究,并以组织样本免疫组化与表达研究补充。

主要发现

  • 心衰心脏间质纤维化伴交联胶原突出,存在活化肌成纤维细胞,组织TGF-β1、赖氨酰氧化酶、骨膜蛋白及骨桥蛋白水平升高。
  • 心衰来源成纤维细胞主要为增殖或非增殖性肌成纤维细胞,具成熟α-平滑肌肌动蛋白应力纤维,高表达促纤维化细胞因子且TGF-β1通路激活。
  • 抑制心衰肌成纤维细胞TGF-β1受体激酶促去分化,伴α-平滑肌肌动蛋白丢失与应力纤维解聚,促纤维化基因及细胞因子表达降至非心衰水平。

临床怎么用

  • 终末期心衰纤维化并非不可逆,肌成纤维细胞表型可调控,支持开发靶向肌成纤维细胞的抗纤维化治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Interstitial fibrosis is an important component of diastolic, and systolic, dysfunction in heart failure (HF) and depends on activation and differentiation of fibroblasts into myofibroblasts (MyoFb). Recent clinical evidence suggests that in late-stage HF, fibrosis is not reversible. OBJECTIVES: The study aims to examine the degree of differentiation of cardiac MyoFb in end-stage HF and the potential for their phenotypic reversibility. METHODS: Fibroblasts were isolated from the left ventricle of the explanted hearts of transplant recipients (ischemic and dilated cardiomyopathy), and from nonused donor hearts. Fibroblasts were maintained in culture without passaging for 4 or 8 days (treatment studies). Phenotyping included functional testing, immunostaining, and expression studies for markers of differentiation. These data were complemented with immunohistology and expression studies in tissue samples. RESULTS: Interstitial fibrosis with cross-linked collagen is prominent in HF hearts, with presence of activated MyoFbs. Tissue levels of transforming growth factor (TGF)-β1, lysyl oxidase, periostin, and osteopontin are elevated. Fibroblastic cells isolated from HF hearts are predominantly MyoFb, proliferative or nonproliferative, with mature α-smooth muscle actin stress fibers. HF MyoFb express high levels of profibrotic cytokines and the TGF-β1 pathway is activated. Inhibition of TGF-β1 receptor kinase in HF MyoFb promotes dedifferentiation of MyoFb with loss of α-smooth muscle actin and depolymerization of stress fibers, and reduces the expression of profibrotic genes and cytokines levels to non-HF levels. CONCLUSION: MyoFb in end-stage HF have a variable degree of differentiation and retain the capacity to return to a less activated state, validating the potential for developing antifibrotic therapy targeting MyoFb.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Nagaraju CK, Robinson EL, Abdesselem M, et al. Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure. J Am Coll Cardiol. 2019. PMID: 31072570. doi:10.1016/j.jacc.2019.02.049

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。